Timothy Endy | Disease X and CHIKV Project Leader

Timothy Endy, Disease X and CHIKV Project Leader, CEPI

Dr. Endy is currently the Program Leader at the Coalition for Epidemic Preparedness Innovations (CEPI) for Disease X and Chikungunya Vaccines.  He is a Professor Emeritus and former Chair of the Department of Microbiology and Immunology and Chief of the Infectious Disease Division at the State University of New York, Upstate Medical University in Syracuse, NY.  Prior to this Dr. Endy was 24 years in the U.S. Army with his career in the Medical Research and Material Command holding positions as Chief of Virology at the overseas lab in Bangkok, Thailand; Chief of Virology at USAMRIID, Ft Detrick MD, and Director of CD&I at WRAIR. Dr. Endy is a Board-Certified physician in the subspecialty of Infectious Diseases and Internal Medicine and did his residency and fellowship training at the Walter Reed Army Medical Center, Washington, DC.  Dr. Endy obtained his medical school training at the Uniformed Services University, F. Edward Herbert School of Medicine, Bethesda, MD; received an MPH in Epidemiology from the University of Michigan, School of Public Health, Ann Arbor, MI; and a BS degree from the Pennsylvania State University, University Park, PA.  Dr. Endy has a broad area of expertise in the field of Clinical and Translational Research.  He has conducted basic science research in the field of virology, developed vaccine field and epidemiological study sites in Southeast and Central Asia, conducted phase I and II clinical vaccine trials and is active in the development and management of research programs that are product oriented towards developing vaccines and diagnostics that meet FDA regulatory requirements.  Dr. Endy is considered an international expert in the field of dengue and dengue hemorrhagic fever and emerging viral pathogens. Dr. Endy is an active reviewer for peer reviewed journals, a subject matter expert on dengue and dengue vaccine development and a NIH funded researcher conducting studies on dengue in Thailand.  He has published over 150 manuscripts in peer reviewed journals, published 12 book chapters and has presented to numerous international conferences and symposiums. 


Day 1 - Tuesday 2nd April @ 16:30

Keynote panel: Defining and developing broadly protective vaccines

  • How do we develop and evaluate the effectiveness second/next generation vaccines
  • Lesson learned in universal flu vaccine efforts
  • What developments have been made towards broadly protective vaccines?

Day 2 - Wednesday 3rd April @ 15:25

Panel: Vaccine development and efforts towards eradicating Chikungunya

last published: 26/Feb/24 13:16 GMT

back to speakers